

Document Detail

Туре:	PMF IBTS SPEC
Document No.:	IBTS/PMF/SPEC/0221[3]
Title:	FRESH FROZEN PLASMA SUITABLE FOR NEONATAL USE
Owner:	QA DOC CON QA DOC CONTROL
Status	CURRENT
Effective Date:	18-Apr-2021
Expiration Date:	04-Aug-2025

Sign-off By

Review

Review: IBTS PMF REVIEW

Level Owner Role

10		The Hole	Tetor	oigh on by
	1 DO	CUMENT CONTROLLER	REBECCA WALDEN	REBECCA WALDEN
	2 QU	ALITY ASSURANCE WRITER IBTS	REBECCA WALDEN	REBECCA WALDEN
	3 LA	BS PHS DIR IBTS	BARRY DOYLE	BARRY DOYLE
	3 NA	TIONAL MEDICAL DIRECTOR	STEPHEN FIELD	STEPHEN FIELD
	4 QU	ALITY ASSURANCE REVIEWER IBTS	COLIN JOHNS	COLIN JOHNS
	Revi	ew: IBTS DOC PERIODIC REVIEW		
Le	vel Ow	vner Role	Actor	<u>Sign-off By</u>
	1 DO	CUMENT CONTROLLER	REBECCA WALDEN	REBECCA WALDEN
	2 QU	ALITY ASSURANCE WRITER IBTS	REBECCA WALDEN	REBECCA WALDEN
	3 NA	TIONAL MEDICAL DIRECTOR	TOR HERVIG	TOR HERVIG
	3 CO	MPONENTS HEAD OF DEPT MRTC	AINE FITZPATRICK	AINE FITZPATRICK
	3 LA	BS PHS DIR IBTS	BARRY DOYLE	BARRY DOYLE
	3 SSC	CD HEAD OF DEPT IBTS	AILEEN FARRELLY	AILEEN FARRELLY
	4 QU	ALITY ASSURANCE REVIEWER IBTS	COLIN JOHNS	COLIN JOHNS
	4 DIF	RECTOR OF QUALITY	KAREN BYRNE	KAREN BYRNE

Actor

Change Orders

Changes as described on Change Order:

Change Order No.

Change Orders - Incorporated

Changes as described on Change Order:

Change Order No. IBTS/CO/0167/21

IRISH BLOOD TRANSFUSION SERVICE

PRODUCT MASTER FILE

TITLE: FRESH FROZEN PLASMA SUITABLE FOR **NEONATAL USE**

Change Description:

Revise IBTS/PMF/SPEC/0203 - 0218, 0220, 0221, 0224, 0226, 0227, 0232, 0236 to update the product labels in the appendices for each product.

Reason for Change:

Fix to the labels as part of the semester patch reference CC 126/19/IBTS and reference status cupper Minister IBTS/QA/IQ/0600 Deviation 008

Change order No.:

IBTS/CO/0167/21

Referenced Documents

BT – 0196 BT - 0605

SmartSolve Roles N/A

Training Type N/A

SmartSolve Document Category

Category	Mobile	Cryobiology	Website	GDP
Yes / No	No	No	Yes	No

IRISH BLOOD TRANSFUSION SERVICE

PRODUCT MASTER FILE

Title: Fresh Frozen Plasma Suitable For Neonatal Use

Name of Product: Fresh Frozen PLASMA Suitable For Neonatal Use

E Progesa Codabar Component Code: 18266

E Progesa ISBT-128 Component Code:

General Specification

General Description: Plasma obtained from a unit of whole blood, rapidly frozen to a temperature that will adequately maintain the activity of labile coagulation factors in a functional state. The majority of leucocytes are removed by filtration of the whole blood. The selected donors meet the additional criteria for neonatal use. Prepared from male donors only.

C4048V00

General Specification:				
Parameter	Quality Requirement	Frequency of Control		
Volume	220 - 300 ml	100 %		
Factor VIIIC	> 0.7 IU/ml	10 per 3 months		
Platelet Content	< 30 x 10 ⁹ /L	4 per month		
Leucocyte Content	< 1 x 10 ⁶ /unit	4 per month		
Red cell presence	Absent when examined macroscopically	100%		
Total Protein	≥50g/l	10 per 3 months		
ABO Agglutinins	No HighTitre Anti-A or Anti-B	100%		
CMV	CMV ab negative	100%		

Labelling:

IBTS/PMF/SPI	EC/0221	Ver 3	Page 4 of 9	
Storage:	Fresh Frozen Plasma Suitable For Neonatal Use should be stored at a core temperature of ≤-25°C for a maximum of 12 months. Once thawed, Fresh Frozen Plasma Suitable For Neonatal Use must not be refrozen and should be used immediately. If delay is unavoidable, the component should be stored at ambient temperature and used within 6 hours.			
Thawing:	Thaw by placing in a 37°C controlled dedicated water bath in the plastic overwrap <u>or</u> by removing the overwrap and placing in a validated microwave plasma defroster.			
Transportation:	The air temperature of the transport container for units of Fresh Frozen Plasma Suitable For Neonatal Use should be maintained \leq -25°C during transportation from the Irish Blood Transfusion Service to the place where they are intended for use. Unless Fresh Frozen Plasma Suitable F Neonatal Use is to be thawed for immediate therapeutic use, it should be transferred immediately to storage at the recommended temperature, \leq 25°C.			
Indications for Use:	coagulation d multiple coag Fresh Frozen	isorders, particularly ulation deficit exists. Plasma Suitable For I	Neonatal Use may be used in in those clinical situations in which a Neonatal Use should not be used	
Menin	1.	e of immunoglobulin	n the absence of a coagulation defici s.	
Precautions In Use:		ozen Plasma Suitable nt with intolerance to	For Neonatal Use should not be used plasma proteins.	
	where po		Frozen Plasma should be used and d bearing age and younger should na.	
	properly be verifie 11.). No the thaw	controlled environme ed to exclude any defe insoluble cryoprecipit procedure.	uld be thawed in the vacuum pack in nt and the integrity of the pack shoul ects or leakages (see Appendices 1 an ate should be visible on completion of	
	intravenc	ously through a set con	For Neonatal Use should be infused ntaining an inline 170-200 µm filter.	
	• No soluti	on should be added to	the bag or giving set.	
		ozen Plasma should no	ot be used where a suitable viral	

inactivated alternative product is available.

Adverse Effects Include:

- <u>Circulatory overload</u>
- <u>Haemolytic transfusion reaction due to transfusion of ABO-</u> incompatible plasma in the component.
- <u>Non-haemolytic transfusion reaction</u> (mainly chills, fever and urticaria). The risk is reduced by leucodepletion.
- <u>Anaphylaxis</u>
- Pathogen transmission
 - Despite careful donor selection and laboratory screening procedures, infections including Syphilis, Viral Hepatitis, HIV, HTLV 1 & 11 and other viruses and protozoa (e.g. malaria) may, in rare instances, occur.
 - vCJD transmission
 - Transmission of other pathogens that are not tested for or recognised.
 - The risk of CMV transmission is minimal as the components are leucodepleted
 - Sepsis due to bacterial contamination (reduced but not eliminated by bacterial screening)
- Metabolic upset
 - Citrate toxicity, especially in neonates and in patients with impaired hepatic function.
- Immunological effects
 - Alloimunisation to HLA and HPA antigens
 - Post Transfusion purpura (PTP), especially in parous female recipients
 - The risk of Graft vs Host Disease (GvHD) in immuno compromised recipients is eliminated by irradiation
 - Transfusion related Acute Lung injury (TRALI) by donor HLA/granulocyte antibodies

Serious Adverse Reaction

Jerify when in

Please inform the IBTS immediately about any event relating to suspected bacterial sepsis/ transfusion associated bacterial sepsis

Serious adverse reactions should be reported to:

National Haemovigilance Office

Irish Blood Transfusion Service National Blood Centre James's Street Dublin 8

AND

Quality Assurance Manager Irish Blood Transfusion Service

AT EITHER

	IBTS/PMF/SPEC/0221		Ver 3	Page 6 of 9
	National Blood Centre James's Street Dublin 8 OR Munster Regional Transfusion Centre St Finbart's Hospital Douglas Road, Cork			
				oril 2021
			dive 1	5 Kr
			othin thee	
	atus	ري	<u>8</u> 2	
	in Use.			
	ift when i			
	New.			


IBTS/PMF/SPEC/0221	Ver 3	Page 7 of 9		
	APPENDIX I			
E Progesa Codabar Component Co	ode: 18266			
E Progesa ISBT -128 Component Code: C4048V00				
Product Name Fresh Frozen PLASMA Suitable for Neonatal Use	Code: C4048	Shelf Life 365 days		
Labelling and Barcode: (for illustration purposes only – barcodes	not suitable for scanning	g – label not to scale)		
2		IBTS ver 2.0		
Fresh Frozen PLASMA Suitable for Neonatal Use Store Frozen at ≤ - 25 °C	AB			
021088	CMV Antibody Negative	ive		
are visible signs of deterioration. This	220882359 xpiry 29 Mar 2022 23:5	9		
component may transmit infection Use within 6 hours of thawing TIME THAWED: DATE:				
18266 Expiry 29/03	/2022 AB Neg			

18266

Expiry 29/03/2022



APPENDIX II



APPENDIX III

